Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

ESMO 2019: Dr. Bekaii-Saab Highlights Important Trials in GI Malignancies

September 29th 2019

ESMO 2019: Dr. Mirza on Important Trials with PARP Inhibitors in Ovarian Cancer

September 29th 2019

ESMO 2019: Dr. McGregor Highlights Impactful 2019 Prostate Cancer Studies

September 29th 2019

ESMO 2019: Dr. Spigel Highlights Progress in Lung Cancer

September 29th 2019

ESMO 2019: Dr. Rugo Highlights Progress in Breast Cancer

September 29th 2019

ESMO 2019: Dr. O'Shaughnessy Highlights Progress in Breast Cancer

September 29th 2019

ESMO 2019: Dr. Choueiri Discusses Novel Treatment Strategies in GU Cancers

September 29th 2019

ESMO 2019: Dr. Hamid Discusses Exciting Immunotherapy Data in Melanoma

September 29th 2019

ESMO 2019: Dr. Ramalingam Discusses Confirmatory Data in Advanced NSCLC

September 29th 2019

OncLive News Network On Location: ESMO 2019 Day 3

September 29th 2019

OncLive News Network On Location: ESMO 2019 Day 2

September 29th 2019

OncLive News Network On Location: ESMO 2019 Day 1

September 29th 2019

Apalutamide Linked to OS Benefit in Nonmetastatic CRPC

September 27th 2019

The next-generation androgen receptor apalutamide, in combination with androgen deprivation therapy, demonstrated a 25% reduction in the risk of death compared with placebo/ADT in patients with nonmetastatic castration-resistant prostate cancer in the phase III SPARTAN trial.

Dr. Henderson on Accessibility of Proton Therapy in Prostate Cancer

September 25th 2019

Randal H. Henderson, MD, MBA, discusses accessibility of proton therapy versus intensity-modulated radiation therapy in prostate cancer.

Dr. Kohli on the Challenges of Molecular Classification in Prostate Cancer

September 25th 2019

Manish Kohli, MD, discusses the challenges of molecular classification in prostate cancer.

The Prostate Cancer Paradox Revisited

September 25th 2019

Conflicting guidelines on prostate-specific antigen testing have affected trends on disease presentation and, potentially, the treatment outcomes for many men with this disease. New agents and powerful new imaging tools have added yet more complexity to the decision process. Therefore, more investigation and cooperation on multiple levels is needed to define appropriate standards of care.

Genetic Testing Gaining Larger Role in Prostate Cancer

September 18th 2019

Leonard G. Gomella, MD, FACS, discusses the role of genetic testing and emerging biomarkers in prostate cancer.

FDA Approves Apalutamide for Metastatic Castration-Sensitive Prostate Cancer

September 18th 2019

The FDA has approved apalutamide for the treatment of patients with metastatic castration-sensitive prostate cancer.

Dr. George on the Use of Radium-223 in Prostate Cancer

September 18th 2019

Daniel J. George, MD, professor of medicine and surgery, member, Duke Cancer Institute, discusses the use of radium-223 dichloride (Xofigo) in prostate cancer.

Carboplatin/Cabazitaxel Combo Shows PFS Benefit in mCRPC

September 17th 2019

The combination of cabazitaxel in combination with carboplatin demonstrated an improvement in progression-free survival versus cabazitaxel alone in men with metastatic castration-resistant prostate cancer.